Will - Pharma SA
27.1 FTEThe score of Will - Pharma shows with a free account.
See the score- Summary? / 5
- Solvency
- Liquidity
- Interest coverage
- Profitability
- Leverage
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Revenue +12 % Equity -46 % Total assets -46 % Headcount (avg FTE) +5 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Will - Pharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | €17.8m | ||||
| Net result | 358,166 € | ||||
| Equity | €4.66m | ||||
| Cash | €1.54m | ||||
| EBITDA | €1.22m | ||||
| Total assets | €9.73m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 06 Jul 2026
- Year ended 31 Dec 2024filed on 27 Jun 2025
- Year ended 31 Dec 2023filed on 17 Jul 2024
- Year ended 31 Dec 2022filed on 25 Jul 2023
- Year ended 31 Dec 2021filed on 25 Jul 2022
Will - Pharma's financial analysis
- Solvency47.9%sector median: 34.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Will - Pharma
Will - Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0402.018.775
- VAT number
- BE0402018775
- Peppol
- Registered · 0208:0402018775 · as of 25 Oct 2026
- Legal form
- SA
- Incorporated
- 07 Oct 1960
- Registered office
- 1301 Wavre
- Size
- Small · 27.1 FTE
- Latest accounts
- 2025 · filed on 06 Jul 2026
- Activity
- Manufacture of medicaments (NACE 21201)
Will - Pharma (SA) has been based in Wavre since 1960, active in: manufacture of medicaments. For 2025, it reports revenue of €17.8m, a net profit of 358,166 € and equity of €4.66m. With 27.1 full-time equivalents, it is a small enterprise by headcount. Its solvency stands at 47.9%, above the median of its sector (34.4%).
Companies similar to Will - Pharma
Companies in the same business, of comparable size and area, outside its group.
- Neogen Manufacture of pharmaceutical preparations Anderlecht · balance sheet €15.2m
- Conforma Manufacture of pharmaceutical preparations Destelbergen · balance sheet €16.3m
- Besins Healthcare Pharmtech Manufacture of pharmaceutical preparations Seraing · balance sheet €23.7m
- KELA - Kempisch Laboratorium - Kela Laboratoria Manufacture of pharmaceutical preparations Hoogstraten · balance sheet €63.2m
- Odyssea Pharma Manufacture of pharmaceutical preparations Grâce-Hollogne · balance sheet €91.0m
- 272BIO Manufacture of pharmaceutical preparations Ghent · balance sheet 709,601 €
- S.A. Laboratoires Pharmaceutiques Trenker Manufacture of basic pharmaceutical products Nivelles · balance sheet €16.1m
- Baxter Manufacture of pharmaceutical preparations Lessines · balance sheet €160.0m
Frequently asked questions about Will - Pharma
What is the revenue of Will - Pharma?
According to the 2025 annual accounts filed with the NBB, the revenue of Will - Pharma amounts to 17,801,611 €.
What is the VAT number of Will - Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0402018775 for Will - Pharma, if the company is VAT-registered. Its company number (CBE) is 0402.018.775.
Where is the registered office of Will - Pharma?
According to the CBE register, the registered office of Will - Pharma is in 1301 Wavre.
What is the equity of Will - Pharma?
At the close of the 2025 financial year, the equity of Will - Pharma amounts to 4,664,446 €, a solvency of 47.9% of total assets.
How many people work at Will - Pharma?
27.1 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Will - Pharma?
The register lists 4 active mandates at Will - Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Will - Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →